Please ensure Javascript is enabled for purposes of website accessibility

Fox Channels May Go Dark on YouTube TV From Wednesday Over Payment Dispute

2 hours ago

California Republicans Sue to Block Congressional Redistricting Plan

2 hours ago

Leaders, Journalist Groups React to Israeli Gaza Strike That Killed Five Journalists

6 hours ago

Trump To Sign Executive Order Directing AG To Prosecute Flag Desecration

8 hours ago

Trump Signs Orders Aimed At Ending Cashless Bail Policies

8 hours ago

Fresno County DUI Crash Sends Car Into Embankment Near Highway 99

10 hours ago

Wrongly Deported Migrant Abrego Again Detained by US Immigration Officials

10 hours ago

Fresno County Wildfire Burns 3,338 Acres, Evacuation Orders Issued

11 hours ago
Can Oxford University Deliver COVID Vaccine for High Risk Groups by October?
TLBBHMAP3-U010ALB5ANM-348f959abae2-512-300x300-1
By Jim Jakobs, Digital Producer
Published 5 years ago on
July 21, 2020

Share

No early safety concerns.

Strong immune responses in both parts of the immune system.

Portrait of Dr. Adrian Hill

“We are seeing good immune response in almost everybody. What this vaccine does particularly well is, trigger both arms of the immune system.” — Dr. Adrian Hill, director, Jenner Institute at Oxford University

Those are the results from Oxford University’s Jenner Institute the world has been waiting for regarding a potential COVID-19 vaccine.

The most optimistic timeline is that the vaccine could be available on an emergency basis for high-risk groups as early as October.

British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are designed to evaluate the safety and gauge the immune response but don’t reveal if the vaccine truly protects.

US Trial of Vaccine Expected Soon

In research published Monday in the journal Lancet, scientists said that they found that the experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 lasting at least two months after injection.

A single dose of the vaccine dubbed AZD1222 resulted in a four-fold increase in antibodies to the SARS-CoV-2 virus spike protein in 95% of participants one month after injection. In all participants, a T-cell response was induced, peaking by day 14, and maintained for two months.

The experimental COVID-19 vaccine caused minor side effects like fever, chills, and muscle pain more often than in those who received a control meningitis vaccine.

“We are seeing good immune response in almost everybody,” said Dr. Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does particularly well is, trigger both arms of the immune system,” he said.

Hill said that larger trials evaluating the vaccine’s effectiveness, involving about 10,000 people in the U.K. as well as participants in South Africa and Brazil are ongoing. Another trial is slated to start in the U.S. soon, aiming to enroll about 30,000 people.

Professor Andrew Pollard, chief investigator of the Oxford Vaccine Trial and co-author of the trial, said, “We saw the strongest immune response in participants who received two doses of the vaccine, indicating that this might be a good strategy for vaccination.”

Image of a British doctor taking blood samples from a patient for COVID-19 research
A doctor takes blood samples for use in a coronavirus vaccine trial in Oxford, England, Thursday, June 25, 2020. Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. (John Cairns, University of Oxford via AP)

October or December Timeframe

A report in the Economist says Oxford’s vaccine is in three late-stage trials. Only one other vaccine, developed by Sinopharm, a Chinese firm, has started a late-stage trial, and it does not have the global support and financing that Oxford’s does.

It might be clear by the end of August if the vaccine is effective. A single successful trial showing efficacy would allow a regulator to approve the vaccine for emergency use — something that would probably pave the way for use in high-risk groups. That could happen in October. The firm thinks that full approval, which would require results from multiple trials, could come early in 2021.

How quickly scientists determine the vaccine’s effectiveness will depend largely on how much more transmission there is, but Hill estimated that if there were enough data to prove the vaccine’s efficacy, immunization of some high-risk groups in Britain could begin in December.

Vaccine Distribution

Oxford is working with the U.K.-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture, and potential distribution of the vaccine, with plans for clinical development and production of the Oxford vaccine progressing globally.

Emergent BioSolutions Inc. will support the manufacturing of AstraZeneca’s vaccine candidate for COVID-19, AZD1222. Under the agreement, valued at approximately $87 million, Emergent will provide development services, technology transfer, analytical testing, drug substance process and performance qualification and will reserve certain large-scale manufacturing capacity through 2020.

Mike Neri, Emergent’s Senior Director of Corporate Communications tells GV Wire℠ by email, “The work is being done in Baltimore, Maryland.”

AstraZeneca’s AZD1222 is one of several candidates supported by Operation Warp Speed (OWS), the U.S. government’s program to accelerate the development, manufacturing, and distribution of COVID-19 medical countermeasures.

Numerous countries including Germany, France, the Netherlands, Italy, U.S,. and the U.K. have all signed deals to receive hundreds of millions of doses of the Oxford vaccine.

Image of vaccine blood samples at Oxford University
Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. In research published Monday, July 20, 2020, in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. (John Cairns, University of Oxford via AP)

‘Challenge’ Trial

Hill said researchers were also considering conducting a “challenge” trial by the end of 2020, an ethically controversial test where participants would be deliberately infected with COVID-19 after being immunized to see if the vaccine is effective.

“This has been done before in 19 different infectious diseases to develop vaccines and drugs and is likely to happen for COVID-19 as well,” he said.

Progress of Other Vaccines

Associated Press reported that Chinese researchers also published a study on their experimental COVID-19 vaccine in the Lancet on Monday. That vaccine uses a technique similar to Oxford’s. They reported that in a study of about 500 people, an immune response was detected in those who were immunized. But the Chinese scientists were unable to detect if people were protected from the disease because they weren’t exposed to COVID-19 afterwards.

Last week, American researchers announced that the first COVID-19 vaccine tested there boosted people’s immune systems just as scientists had hoped and the shots will now enter the final phase of testing. That vaccine, developed by the National Institutes of Health and Moderna, produced the molecules key to blocking infection in volunteers who got it, at levels comparable to people who survived a COVID-19 infection.

(Associated Press contributed to this report.)

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Fresno County Crash With Semi-Truck Leaves Man Dead

DON'T MISS

Fox Channels May Go Dark on YouTube TV From Wednesday Over Payment Dispute

DON'T MISS

California Republicans Sue to Block Congressional Redistricting Plan

DON'T MISS

Two Students Arrested After Fight at Visalia’s Redwood High School

DON'T MISS

Trump Wants to Meet North Korea’s Kim This Year, He Tells South Korea

DON'T MISS

Fresno Police Arrest Man After Shooting and Stabbing Leave Two Hospitalized

DON'T MISS

Entz: Bulldogs Must ‘Learn, Burn, Return’ After Kansas Loss

DON'T MISS

Caleb Quick’s Father, Other Parents Protest at Fresno Court to Repeal Prop 57

DON'T MISS

SF Has Avoided Trump’s Ire Until Now. Will He Send National Guard?

DON'T MISS

Lil Nas X Pleads Not Guilty to Felony Charges of Assaulting Police

UP NEXT

California Republicans Sue to Block Congressional Redistricting Plan

UP NEXT

Trump Wants to Meet North Korea’s Kim This Year, He Tells South Korea

UP NEXT

SF Has Avoided Trump’s Ire Until Now. Will He Send National Guard?

UP NEXT

Leaders, Journalist Groups React to Israeli Gaza Strike That Killed Five Journalists

UP NEXT

CA Bill To Give Interest On Insurance Payments To Homeowners

UP NEXT

Trump To Sign Executive Order Directing AG To Prosecute Flag Desecration

UP NEXT

Trump Signs Orders Aimed At Ending Cashless Bail Policies

UP NEXT

US National Guard Troops in Washington to Begin Carrying Weapons, Officials Say

UP NEXT

Israel Hits Gaza Hospital, Killing at Least 20 People, Including 5 Journalists

UP NEXT

Trump to Sign Orders Aimed at Ending Cashless Bail Policies

Two Students Arrested After Fight at Visalia’s Redwood High School

2 hours ago

Trump Wants to Meet North Korea’s Kim This Year, He Tells South Korea

3 hours ago

Fresno Police Arrest Man After Shooting and Stabbing Leave Two Hospitalized

3 hours ago

Entz: Bulldogs Must ‘Learn, Burn, Return’ After Kansas Loss

3 hours ago

Caleb Quick’s Father, Other Parents Protest at Fresno Court to Repeal Prop 57

4 hours ago

SF Has Avoided Trump’s Ire Until Now. Will He Send National Guard?

5 hours ago

Lil Nas X Pleads Not Guilty to Felony Charges of Assaulting Police

6 hours ago

Leaders, Journalist Groups React to Israeli Gaza Strike That Killed Five Journalists

6 hours ago

CA Bill To Give Interest On Insurance Payments To Homeowners

6 hours ago

Bakersfield Man Pleads Guilty to Shining Laser at Sheriff’s Helicopter

7 hours ago

Fresno County Crash With Semi-Truck Leaves Man Dead

A 45-year-old man was killed Monday afternoon in a crash involving a passenger car and a semi-truck in southeastern Fresno County, authoriti...

2 hours ago

fresno
2 hours ago

Fresno County Crash With Semi-Truck Leaves Man Dead

YouTube app is seen on a smartphone in this illustration taken, July 13, 2021. (Reuters File)
2 hours ago

Fox Channels May Go Dark on YouTube TV From Wednesday Over Payment Dispute

California Governor Gavin Newsom, along with local congressional representatives, state officials and supporters, speaks as he announces the redrawing of California's congressional maps, calling on voters to approve a ballot measure, in response to a similar move in Texas being supported by U.S. President Donald Trump, in Los Angeles, California, U.S., August 14, 2025. (Reuters File)
2 hours ago

California Republicans Sue to Block Congressional Redistricting Plan

2 hours ago

Two Students Arrested After Fight at Visalia’s Redwood High School

U.S. President Donald Trump meets with South Korean President Lee Jae Myung at the Oval Office, at the White House, in Washington, D.C., U.S., August 25, 2025. (Reuters/Brian Snyder)
3 hours ago

Trump Wants to Meet North Korea’s Kim This Year, He Tells South Korea

3 hours ago

Fresno Police Arrest Man After Shooting and Stabbing Leave Two Hospitalized

Fresno State head coach Matt Entz
3 hours ago

Entz: Bulldogs Must ‘Learn, Burn, Return’ After Kansas Loss

Parents in Fresno County are calling for reforms to California’s Proposition 57, arguing it allows violent juvenile offenders to receive lighter sentences and slows prosecution, while providing support for families who have lost children to teen violence. (GV Wire)
4 hours ago

Caleb Quick’s Father, Other Parents Protest at Fresno Court to Repeal Prop 57

Search

Help continue the work that gets you the news that matters most.

Send this to a friend